92results about How to "Treatment stable" patented technology

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

In a system for separating crystals from sludge, or from separated water generated when sludge is subjected to a concentration process or a dewatering process, aspects of both phosphorus removal and phosphorus recovery can be satisfied, MAP having a high degree of purity can be recovered, and stable treatment can be performed such that the MAP recovery rate is high and blockages of a liquid cyclone do not occur. An aspect of the present invention is a crystal separation apparatus for separating crystals from sludge, or from separated water generated when sludge is subjected to a concentration process or a dewatering process, comprising a liquid cyclone for separating the crystals from the sludge or separated water introduced into the liquid cyclone, and a return pipe A for returning the sludge or separated water which flows out from an overflow riser of the liquid cyclone to a sludge or separated water introduction portion of the liquid cyclone.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

A plasma treatment method comprising exhausting a process chamber so as to decompress the process chamber, mounting a wafer on a suscepter, supplying a process gas to the wafer through a shower electrode, applying high frequency power, which has a first frequency f1 lower than an inherent lower ion transit frequencies of the process gas, to the suscepter, and applying high frequency power, which has a second frequency f2 higher than an inherent upper ion transit frequencies of the process gas, whereby a plasma is generated in the process chamber and activated species influence the wafer.

The invention discloses a clinical treatment device for diabetes, which comprises a sickbed; one side of the sickbed is provided with a slide base, and a thread rod is arranged in the slide base; a thread slide block connected to the thread rod is arranged in the slide base, and the thread slide block is connected with a vertical frame; the upper end of the vertical frame is connected with a horizontal second slide base, and a second thread rod is arranged in the second slide base; the second thread base is connected with a second slide block arranged in the second slide base, the second slideblock is fixedly connected with a slide plate; an electric push rod is mounted on the slide plate, and the lower end of the electric push rod is connected with a massage device. The clinical treatment device is stable in structure and running, and convenient to control, high in degree of automation, and stable in treatment; the clinical treatment device has the advantages of realizing the massagetreatment after the clinical operation of diabetes, effectively relieving stomachache and unsmooth abdominal food circulation of patients, greatly promoting the patient recovery, and meeting the current using demand.

The present invention relates to one kind of Chinese herbal medicine capsule for treating diabetes and its complications. The Chinese herbal medicine capsule is prepared with nine kinds of Chinese medicinal materials, including buckwheat, kudzu vine root, tuckahoe, wolfberry fruit, Chinese yam, etc and through one unique preparation process. It has the functions of promoting blood circulation to disperse blood clots, clearing away heat, moistening dryness, and invigorating kidney and spleen, and can condition the internal organs comprehensively to reach diabetes and its complications radically. It has the advantages of fast acting, short treating period, no toxic side effect, simple preparation process, low cost, etc.

Disclosed is a biological desulfurization apparatus including a reaction tower 1 into which biogas generated by anaerobic fermentation of organic waste is to be introduced, a carrier-packed layer 2a, 2b arranged in the reaction tower and provided with a carrier to which microorganisms have adhered, an air feeding pipe 3 that mixes air into a lower part of the reaction tower, and a sprinkling mechanism 7 that sprinkles water on an upper part of the reaction tower, wherein the carrier-packed layer is arranged in two or more stages.

In a system for separating crystals from sludge, or from separated water generated when sludge is subjected to a concentration process or a dewatering process, aspects of both phosphorus removal and phosphorus recovery can be satisfied, MAP having a high degree of purity can be recovered, and stable treatment can be performed such that the MAP recovery rate is high and blockages of a hydrocyclone do not occur. An aspect of the present invention is a crystal separation apparatus for separating crystals from sludge, or from separated water generated when sludge is subjected to a concentration process or a dewatering process, comprising a hydrocyclone for separating the crystals from the sludge or separated water introduced into the hydrocyclone, and a return pipe A for returning the sludge or separated water which flows out from an overflow riser of the hydrocyclone to a sludge or separated water introduction portion of the hydrocyclone.

The present invention provides parathyroid hormone and / or parathyroid hormone-related protein analogs, compositions thereof and methods thereto.

The invention provides a process and apparatus for treating water, which can be stably operated with high efficiency over a long period of time. The apparatus has a grounding electrode and a pair of applying electrodes connected to a DC voltage source through a register and first and second high-frequency switches which are controlled by a high-frequency switching commander circuit, to convert DC voltage from the DC voltage source to AC voltage to be fed to the applying electrodes. The high-frequency switching commander circuit is connected to a first high-frequency oscillation circuit connected to a control circuit which is controlled by a second high-frequency oscillation circuit, to provide a signal changing randomly in frequency as output signal from the first high-frequency oscillation circuit. The second high-frequency oscillation circuit also controls a flip-flop circuit connected to the first high-frequency oscillation circuit, to add acutely and momentary frequency fluctuating portions in randomly frequency changing signal from the first oscillation circuit.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

A solid-state VC sodium injection for treating the diseases caused by VC difficiency is prepared from VC sodium, VC and the pharmacologically acceptable additives.

A process recipe is controlled by processing reflection interference light on the surface of a wafer with a signal and etching is carried out by suppressing an increase in the surface roughness of the wafer during etching. That is, a dry etching method for use in a dry etching system comprising means of treating a sample by generating plasma in a vacuum process chamber and monitor means of monitoring the reflection interference light of the sample to be treated, the method comprising the step of detecting the spectrum of reflection interference light on the surface of the sample to be treated, the step of obtaining a residual from curve fit between a theoretical value estimated from the film reflection model of the surface of the wafer and the spectrum of reflection interference light, and the step of judging whether the residual from the curve fit falls within a predetermined value.

The present invention is to provide a hemodialysis system optimized, for example, to suppress fluctuations in blood pressure in accordance with differences between individual patients. This system isconfigured to include: a blood-related information acquiring means for acquiring blood flow information in a hemodialysis blood circuit, and patient biometric information such as peripheral vascular resistance information, blood pressure information, facial information, body movement information, temperature information, and humidity information; an individual difference information management means for acquiring and managing patient individual-difference information from the blood-related information; and an optimized dialysis means for performing dialysis treatment optimized for the patient,on the basis of the patient individual-difference information.

It is an object of the invention to provide a spin finish generating neither tar nor scum in false twisting treatment either of the hot plate contact heating type or of the non-contact heating type using a radiation type high temperature heater and thus enabling long term stable false twisting treatment. This invention provides a spin finish for synthetic fibers which satisfies the following relations (1) and (2): 10<=T<=22 (1) 0<=Re<=0.25 (2) where T is the surface tension (mN / m) of the oil after allowing the same to stand at 220° C. for 1 hour and Re is the percent residue (% by weight) on heating of the oil after allowing the same to stand at 400° C. for 24 hours.

Disclosed is a method of treating, preventing or ameliorating disease using a chimeric protein comprising a cell-binding region and a biologically active region such as a toxin or other cytostatic or cytocidal molecule. The present invention discloses using a chimeric protein to modulate immune response to effectuate improvement in disease. In addition, the present invention teaches a method of targeting disease using the immune system. Finally, the present invention includes a method whereby the immune system may be used to monitor and assess disease progression, particularly with cancer diseases.

The invention discloses a medicine for treating kidney stone and gall-stone, according to a calculus formation pathology and a pharmacological experiment formula, the medicine of the invention is prepared by arbutin, desmodium, lichee nucleus, longan nucleus, common fenugreek seed, gecko, pig iron cinder, gynostemma pentaphylla, plantago, Orthosiphon Stamineus, Caulis aristolochiae manshuriensis, bletilla rhizome, magnolia cortex and sweetleaf tea. The materials are natural-green, safe and reliable. A traditional Chinese medicine toxin expelling therapy is used. The medicine is capable of releasing spasm, relieving pain, smoothing skin, sterilizing, softening hardness and dissipating binds, soothing liver and resolving depression, clearing heat and dispersing stagnate, rectifying qi, disinhibiting urine and freeing strangury and benifiting openheartedness, the medicine can directly act on nidus, an organic matter is subjected to releasing, dissolving and biological enzymatic hydrolysis, can comprehensively permeated in a core of the calculus, the calculus can be cracked, melted and dissolved layer by layer from outer part to inner part, and the waste liquid is excreted through human excretion tissue, and the damaged cells can be activated, the gland can be balanced, the organ vitality can be enhanced, the acid-base value of blood can be balanced, the calculus recurrence can be prevented, and the simultaneous treatment of principal and subordinate symptoms effect can be acted.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.